Gabriel E Molina1, Leyre Zubiri1, Justine V Cohen2, Sienna M Durbin1, Laura Petrillo3, Ian M Allen1, Yonina R Murciano-Goroff4, Michael Dougan5, Molly F Thomas5, Alexander T Faje6, Michelle Rengarajan6, Amanda C Guidon7, Steven T Chen8, Daniel Okin9, Benjamin D Medoff9, Mazen Nasrallah10, Minna J Kohler10, Sara R Schoenfeld10, Rebecca S Karp Leaf1, Meghan E Sise11, Tomas G Neilan12, Daniel A Zlotoff12, Jocelyn R Farmer13, Meghan J Mooradian1, Aditya Bardia1, Minh Mai1, Ryan J Sullivan1, Yevgeniy R Semenov8, Alexandra Chloé Villani14, Kerry L Reynolds1. 1. Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2. Division of Oncology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. 3. Division of Palliative Care, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 5. Division of Gastroenterology, Department of Medicine, Mass General Center for Cancer Research, Division of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 6. Neuroendocrine Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 7. Division of Neuromuscular Disorders, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 8. Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 9. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 10. Division of Rheumatology, Allergy, Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 11. Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 12. Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 13. Division of Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 14. Massachusetts General Hospital Center for Immunology and Inflammatory Diseases. Mass General Center for Cancer Research Division of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: The aim of this study was to characterize severe immune-related adverse events (irAEs) seen among hospitalized patients and to examine risk factors for irAE admissions and clinically relevant outcomes, including length of stay, immune checkpoint inhibitor (ICI) discontinuation, readmission, and death. METHODS: Patients who received ICI therapy (ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, or any ICI combination) at Massachusetts General Hospital (MGH) and were hospitalized at MGH following ICI initiation between January 1, 2011, and October 24, 2018, were identified using pharmacy and hospital admission databases. Medical records of all irAE admissions were reviewed, and specialist review with defined criteria was performed. Demographic data, relevant clinical history (malignancy type and most recent ICI regimen), and key admission characteristics, including dates of admission and discharge, immunosuppressive management, ICI discontinuation, readmission, and death, were collected. RESULTS: In total, 450 admissions were classified as irAE admissions and represent the study's cohort. Alongside the increasing use of ICIs at our institution, the number of patients admitted to MGH for irAEs has gradually increased every year from 9 in 2011 to 92 in 2018. The hospitalization rate per ICI recipient has declined over that same time period (25.0% in 2011 to 8.5% in 2018). The most common toxicities leading to hospitalization in our cohort were gastrointestinal (30.7%; n = 138), pulmonary (15.8%; n = 71), hepatic (14.2%; n = 64), endocrine (12.2%; n = 55), neurologic (8.4%; n = 38), cardiac (6.7%; n = 30), and dermatologic (4.4%; n = 20). Multivariable logistic regression revealed statistically significant increases in irAE admission risk for CTLA-4 monotherapy recipients (odds ratio [OR], 2.02; p < .001) and CTLA-4 plus PD-1 combination therapy recipients (OR, 1.88; p < .001), relative to PD-1/PD-L1 monotherapy recipients, and patients with multiple toxicity had a 5-fold increase in inpatient mortality. CONCLUSION: This study illustrates that cancer centers must be prepared to manage a wide variety of irAE types and that CTLA-4 and combination ICI regimens are more likely to cause irAE admissions, and earlier. In addition, admissions for patients with multi-organ involvement is common and those patients are at highest risk of inpatient mortality. IMPLICATIONS FOR PRACTICE: The number of patients admitted to Massachusetts General Hospital for immune-related adverse events (irAEs) has gradually increased every year and the most common admissions are for gastrointestinal (30.7%), pulmonary (15/8%), and hepatic (14.2%) events. Readmission rates are high (29% at 30 days, 49% at 180 days) and 64.2% have to permanently discontinue immune checkpoint inhibitor therapy. Importantly, multiple concurrent toxicities were seen in 21.6% (97/450) of irAE admissions and these patients have a fivefold increased risk of inpatient death.
BACKGROUND: The aim of this study was to characterize severe immune-related adverse events (irAEs) seen among hospitalized patients and to examine risk factors for irAE admissions and clinically relevant outcomes, including length of stay, immune checkpoint inhibitor (ICI) discontinuation, readmission, and death. METHODS: Patients who received ICI therapy (ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, or any ICI combination) at Massachusetts General Hospital (MGH) and were hospitalized at MGH following ICI initiation between January 1, 2011, and October 24, 2018, were identified using pharmacy and hospital admission databases. Medical records of all irAE admissions were reviewed, and specialist review with defined criteria was performed. Demographic data, relevant clinical history (malignancy type and most recent ICI regimen), and key admission characteristics, including dates of admission and discharge, immunosuppressive management, ICI discontinuation, readmission, and death, were collected. RESULTS: In total, 450 admissions were classified as irAE admissions and represent the study's cohort. Alongside the increasing use of ICIs at our institution, the number of patients admitted to MGH for irAEs has gradually increased every year from 9 in 2011 to 92 in 2018. The hospitalization rate per ICI recipient has declined over that same time period (25.0% in 2011 to 8.5% in 2018). The most common toxicities leading to hospitalization in our cohort were gastrointestinal (30.7%; n = 138), pulmonary (15.8%; n = 71), hepatic (14.2%; n = 64), endocrine (12.2%; n = 55), neurologic (8.4%; n = 38), cardiac (6.7%; n = 30), and dermatologic (4.4%; n = 20). Multivariable logistic regression revealed statistically significant increases in irAE admission risk for CTLA-4 monotherapy recipients (odds ratio [OR], 2.02; p < .001) and CTLA-4 plus PD-1 combination therapy recipients (OR, 1.88; p < .001), relative to PD-1/PD-L1 monotherapy recipients, and patients with multiple toxicity had a 5-fold increase in inpatient mortality. CONCLUSION: This study illustrates that cancer centers must be prepared to manage a wide variety of irAE types and that CTLA-4 and combination ICI regimens are more likely to cause irAE admissions, and earlier. In addition, admissions for patients with multi-organ involvement is common and those patients are at highest risk of inpatient mortality. IMPLICATIONS FOR PRACTICE: The number of patients admitted to Massachusetts General Hospital for immune-related adverse events (irAEs) has gradually increased every year and the most common admissions are for gastrointestinal (30.7%), pulmonary (15/8%), and hepatic (14.2%) events. Readmission rates are high (29% at 30 days, 49% at 180 days) and 64.2% have to permanently discontinue immune checkpoint inhibitor therapy. Importantly, multiple concurrent toxicities were seen in 21.6% (97/450) of irAE admissions and these patients have a fivefold increased risk of inpatient death.
Authors: Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino Journal: N Engl J Med Date: 2018-04-16 Impact factor: 91.245
Authors: Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André Journal: Lancet Oncol Date: 2017-07-19 Impact factor: 41.316
Authors: Magid Awadalla; Syed S Mahmood; John D Groarke; Malek Z O Hassan; Anju Nohria; Adam Rokicki; Sean P Murphy; Nathaniel D Mercaldo; Lili Zhang; Daniel A Zlotoff; Kerry L Reynolds; Raza M Alvi; Dahlia Banerji; Shiying Liu; Lucie M Heinzerling; Maeve Jones-O'Connor; Rula B Bakar; Justine V Cohen; Michael C Kirchberger; Ryan J Sullivan; Dipti Gupta; Connor P Mulligan; Sachin P Shah; Sarju Ganatra; Muhammad A Rizvi; Gagan Sahni; Carlo G Tocchetti; Donald P Lawrence; Michael Mahmoudi; Richard B Devereux; Brian J Forrestal; Anant Mandawat; Alexander R Lyon; Carol L Chen; Ana Barac; Judy Hung; Paaladinesh Thavendiranathan; Michael H Picard; Franck Thuny; Stephane Ederhy; Michael G Fradley; Tomas G Neilan Journal: J Am Coll Cardiol Date: 2020-02-11 Impact factor: 24.094
Authors: Allison Betof Warner; Jessica S Palmer; Alexander N Shoushtari; Debra A Goldman; Katherine S Panageas; Sara A Hayes; Raazi Bajwa; Parisa Momtaz; Margaret K Callahan; Jedd D Wolchok; Michael A Postow; Paul B Chapman Journal: J Clin Oncol Date: 2020-02-13 Impact factor: 44.544
Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Daniel Y Wang; Joe-Elie Salem; Justine V Cohen; Sunandana Chandra; Christian Menzer; Fei Ye; Shilin Zhao; Satya Das; Kathryn E Beckermann; Lisa Ha; W Kimryn Rathmell; Kristin K Ancell; Justin M Balko; Caitlin Bowman; Elizabeth J Davis; David D Chism; Leora Horn; Georgina V Long; Matteo S Carlino; Benedicte Lebrun-Vignes; Zeynep Eroglu; Jessica C Hassel; Alexander M Menzies; Jeffrey A Sosman; Ryan J Sullivan; Javid J Moslehi; Douglas B Johnson Journal: JAMA Oncol Date: 2018-12-01 Impact factor: 31.777
Authors: Michael R Migden; Danny Rischin; Chrysalyne D Schmults; Alexander Guminski; Axel Hauschild; Karl D Lewis; Christine H Chung; Leonel Hernandez-Aya; Annette M Lim; Anne Lynn S Chang; Guilherme Rabinowits; Alesha A Thai; Lara A Dunn; Brett G M Hughes; Nikhil I Khushalani; Badri Modi; Dirk Schadendorf; Bo Gao; Frank Seebach; Siyu Li; Jingjin Li; Melissa Mathias; Jocelyn Booth; Kosalai Mohan; Elizabeth Stankevich; Hani M Babiker; Irene Brana; Marta Gil-Martin; Jade Homsi; Melissa L Johnson; Victor Moreno; Jiaxin Niu; Taofeek K Owonikoko; Kyriakos P Papadopoulos; George D Yancopoulos; Israel Lowy; Matthew G Fury Journal: N Engl J Med Date: 2018-06-04 Impact factor: 91.245
Authors: David Hsiehchen; Abdul Rafeh Naqash; Magdalena Espinoza; Mitchell S Von Itzstein; Alessio Cortellini; Biagio Ricciuti; Dwight H Owen; Mehak Laharwal; Yukihiro Toi; Michael Burke; Yang Xie; David E Gerber Journal: Oncoimmunology Date: 2022-01-05 Impact factor: 8.110
Authors: Leyre Zubiri; Gabriel E Molina; Alexandra-Chloé Villani; Kerry L Reynolds; Meghan J Mooradian; Justine Cohen; Sienna M Durbin; Laura Petrillo; Genevieve M Boland; Dejan Juric; Michael Dougan; Molly F Thomas; Alex T Faje; Michelle Rengarajan; Amanda C Guidon; Steven T Chen; Daniel Okin; Benjamin D Medoff; Mazen Nasrallah; Minna J Kohler; Sara R Schoenfeld; Rebecca S Karp-Leaf; Meghan E Sise; Tomas G Neilan; Daniel A Zlotoff; Jocelyn R Farmer; Aditya Bardia; Ryan J Sullivan; Steven M Blum; Yevgeniy R Semenov Journal: J Immunother Cancer Date: 2021-09 Impact factor: 13.751